Super-enhancer analysis reveals subtypes in AML and MDS
Super-enhancer analysis reveals subtypes in AML and MDS
Novel therapies for older patients with AML and MDS
Better screening programmes needed for haematological malignancies such as leukaemia
Karyotyping a CLL subset with ibrutinib susceptibility
Chemo-genomic interrogation reveals JAK sensitive subgroup in AML
Targeted genome editing in haematopoeitic stem cells
A microRNA driver of B-cell leukaemia
Risk adapted therapy for acute myeloid leukaemia
Evaluation of ibrutinib in treatment of CLL with 17p deletion
An overview of MCL from EHA 2016
The value and strategy for incorporating biosimilars Into clinical practice
Checkpoint inhibitor therapy benefits advanced bladder cancer patients